Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Brain Metastases|Human Epidermal Growth Factor 2 Positive Carcinoma of Breast|Advanced Breast Cancer
Interventions: DRUG: Trastuzumab|DRUG: Trastuzumab Emtansine (T-DM1)|DRUG: Pertuzumab|DRUG: Tucatinib
Sponsor: Carey Anders, M.D.
Collaborators: Seagen Inc.